Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A.
adherence
device
factor VIII delivery
hemophilia A
patient satisfaction
Journal
Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
19
2
2019
pubmed:
19
2
2019
medline:
19
2
2019
Statut:
epublish
Résumé
FuseNGO is a relatively new device consisting of a prefilled dual-chamber syringe (DCS) that was recently introduced for the reconstitution of recombinant factor VIII. Herein, the DCS device was assessed using five questionnaires with the primary aim of evaluating patient perceptions and preferences. An observational, non-interventional, longitudinal study on 86 patients with a confirmed diagnosis of hemophilia A was carried out at 21 sites in Italy. Each patient underwent a baseline visit and final study visit within 3-6 months. Patients were administered five questionnaires: HemoPREF; Treatment Satisfaction Questionnaire for Medication (TSQM); VeritasPRO; Hemophilia Well-being Index (HWBI); Work Productivity and Activity Impairment Questionnaire (WPAI) + Classroom Impairment Questions (CIQ): Hemophilia Specific (HS). Compared to baseline, scores for HemoPREF were higher at follow-up; significant increases in the percentage of positive responses were seen for all questions regarding the ease of use ( Considering patient-reported outcomes, the DCS device was associated with easier preparation, storage, disposal of equipment, and overall use. Of particular note, preparation times were reduced by around 50%. The majority of patients were satisfied with the device and overall adherence scores were high. Considering these results, the device has the potential to increase adherence to therapy and, possibly, reduce healthcare costs.
Sections du résumé
BACKGROUND
BACKGROUND
FuseNGO is a relatively new device consisting of a prefilled dual-chamber syringe (DCS) that was recently introduced for the reconstitution of recombinant factor VIII. Herein, the DCS device was assessed using five questionnaires with the primary aim of evaluating patient perceptions and preferences.
METHODS
METHODS
An observational, non-interventional, longitudinal study on 86 patients with a confirmed diagnosis of hemophilia A was carried out at 21 sites in Italy. Each patient underwent a baseline visit and final study visit within 3-6 months. Patients were administered five questionnaires: HemoPREF; Treatment Satisfaction Questionnaire for Medication (TSQM); VeritasPRO; Hemophilia Well-being Index (HWBI); Work Productivity and Activity Impairment Questionnaire (WPAI) + Classroom Impairment Questions (CIQ): Hemophilia Specific (HS).
RESULTS
RESULTS
Compared to baseline, scores for HemoPREF were higher at follow-up; significant increases in the percentage of positive responses were seen for all questions regarding the ease of use (
CONCLUSION
CONCLUSIONS
Considering patient-reported outcomes, the DCS device was associated with easier preparation, storage, disposal of equipment, and overall use. Of particular note, preparation times were reduced by around 50%. The majority of patients were satisfied with the device and overall adherence scores were high. Considering these results, the device has the potential to increase adherence to therapy and, possibly, reduce healthcare costs.
Identifiants
pubmed: 30774319
doi: 10.2147/PPA.S175254
pii: ppa-13-233
pmc: PMC6362933
doi:
Types de publication
Journal Article
Langues
eng
Pagination
233-240Déclaration de conflit d'intérêts
Disclosure Eleonora Russo and Cristiano Gallucci are employees of Pfizer srl, Italy. The authors report no other conflicts of interest in this work.
Références
Haemophilia. 2001 Jul;7(4):392-6
pubmed: 11442644
Health Qual Life Outcomes. 2004 Feb 26;2:12
pubmed: 14987333
Haemophilia. 2010 Mar;16(2):247-55
pubmed: 19925631
Haemophilia. 2011 Sep;17(5):e901-5
pubmed: 21649798
Haemophilia. 2012 May;18(3):e286-9
pubmed: 21910789
J Thromb Haemost. 2012 Mar;10(3):359-67
pubmed: 22212248
Haemophilia. 2012 Jul;18(4):568-74
pubmed: 22335526
Int J Behav Med. 2013 Dec;20(4):609-17
pubmed: 22948483
J Blood Med. 2013 May 16;4:49-56
pubmed: 23700376
Haemophilia. 2014 Jul;20(4):527-34
pubmed: 24471912
Orphanet J Rare Dis. 2014 Mar 21;9:39
pubmed: 24655371
Blood Transfus. 2014 Apr;12 Suppl 3:s567-75
pubmed: 24922297
Patient Prefer Adherence. 2014 Dec 12;8:1713-20
pubmed: 25525348
J Med Econ. 2015 Jun;18(6):457-65
pubmed: 25660324
Haemophilia. 2015 Sep;21(5):612-21
pubmed: 25858411
J Thromb Haemost. 2015 Jun;13 Suppl 1:S176-9
pubmed: 26149020
Br J Haematol. 2016 Aug;174(3):454-60
pubmed: 27098446
Haemophilia. 2016 Jul;22(4):e245-50
pubmed: 27216992
Farm Hosp. 2016 Nov 01;40(n06):579-603
pubmed: 27894230
Haemophilia. 2017 Jul;23(4):e267-e275
pubmed: 28574162
Haemophilia. 2017 Nov;23(6):884-893
pubmed: 28925586